Remus Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was 11.85%. Remus Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 1.69.
Remus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 7.01%.
Remus Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Remus Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals ROE % Adjusted to Book Value Chart
NSE:REMUS vs MCK, CAH, COR: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.01% mean?
Remus Pharmaceuticals (NSE:REMUS) has a ROE % Adjusted to Book Value of 7.01% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' ROE % Adjusted to Book Value too high?
Remus Pharmaceuticals' current ROE % Adjusted to Book Value is 7.01%. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' ROE % Adjusted to Book Value compare to MCK and CAH?
Remus Pharmaceuticals' ROE % Adjusted to Book Value of 7.01% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current ROE % Adjusted to Book Value is 7.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹746.05 — trading 64% below its estimated fair value. The current ROE % Adjusted to Book Value is 7.01%. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current ROE % Adjusted to Book Value is 7.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹746.05 is trading 64% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
ROE % Adjusted to Book Value: 7.01%
GF Value™: ₹2,071.36 vs. price of ₹746.05 (64% below fair value)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score
Get the complete analysis for NSE:REMUS
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
